OncoMatch/Clinical Trials/NCT06055816
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Is NCT06055816 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Endostar and Envafolimab for nasopharyngeal carcinoma.
Treatment: Endostar and Envafolimab — Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Demographics
Prior therapy
Cannot have received: radiotherapy
Prior radiotherapy
Cannot have received: cytotoxic chemotherapy
cytotoxic chemotherapy
Cannot have received: immunotherapy
immunotherapy
Cannot have received: target therapy
target therapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06055816 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IVA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages